Phibro Animal Health (PAHC) financial statements
Phibro Animal Health reported revenue of $1.5B in fiscal 2026, up 7.9% a year over 9 years.
Net income was $100M and the operating margin 12.8%, against 12.8% in 2017.
Free cash flow was $10M, and the company returned $19M in dividends.
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Phibro Animal Health's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $764M | $820M | $828M | $800M | $833M | $942M | $978M | $1.0B | $1.3B | $1.5B |
| Cost of revenue | $516M | $553M | $563M | $543M | $562M | $657M | $680M | $705M | $896M | $1.0B |
| Gross profit | $248M | $267M | $265M | $257M | $271M | $285M | $298M | $313M | $400M | $513M |
| Research and development | $9M | $10M | $12M | $14M | $18M | $21M | $24M | $29M | $24M | $25M |
| Selling, general and admin | $150M | $168M | $181M | $188M | $197M | $206M | $226M | $260M | $289M | $318M |
| Operating income | $98M | $99M | $83M | $69M | $75M | $79M | $72M | $53M | $110M | $194M |
| Interest expense | $17M | $14M | $14M | $15M | $14M | $13M | $19M | $23M | $37M | $46M |
| Pre-tax income | $81M | $88M | $72M | $56M | $66M | $72M | $54M | $11M | $68M | $137M |
| Income tax | $16M | $23M | $17M | $22M | $12M | $23M | $21M | $8M | $20M | $38M |
| Net income | $65M | $65M | $55M | $34M | $54M | $49M | $33M | $2M | $48M | $100M |
| EPS (diluted) | $1.61 | $1.61 | $1.35 | $0.83 | $1.34 | $1.21 | $0.81 | $0.06 | $1.19 | $2.43 |
| Diluted shares | 40M | 40M | 41M | 41M | 41M | 41M | 41M | 41M | 41M | 41M |
| Gross margin | 32.5% | 32.5% | 32.0% | 32.1% | 32.6% | 30.3% | 30.5% | 30.8% | 30.9% | 33.8% |
| Operating margin | 12.8% | 12.1% | 10.1% | 8.6% | 9.0% | 8.4% | 7.3% | 5.2% | 8.5% | 12.8% |
| Net margin | 8.5% | 7.9% | 6.6% | 4.2% | 6.5% | 5.2% | 3.3% | 0.2% | 3.7% | 6.6% |
Balance sheet
Fiscal years, from Phibro Animal Health's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $56M | $79M | $82M | $91M | $92M | $91M | $81M | $115M | $77M | $82M |
| Receivables | $126M | $136M | $159M | $127M | $147M | $167M | $163M | $169M | $228M | $239M |
| Inventory | $161M | $178M | $198M | $197M | $216M | $259M | $278M | $266M | $444M | $535M |
| Total current assets | $364M | $415M | $466M | $452M | $499M | $566M | $586M | $601M | $811M | $936M |
| Property, plant and equipment | $127M | $130M | $140M | $148M | $155M | $165M | $196M | $203M | $355M | $369M |
| Goodwill | $24M | $27M | $27M | $53M | $53M | $53M | $53M | $55M | $60M | $60M |
| Total assets | $623M | $672M | $727M | $784M | $841M | $932M | $971M | $982M | $1.4B | $1.5B |
| Total current liabilities | $116M | $143M | $154M | $157M | $164M | $191M | $176M | $204M | $293M | $316M |
| Long-term debt | $242M | $230M | $218M | $218M | $297M | $273M | $312M | $282M | $615M | — |
| Total liabilities | $472M | $487M | $511M | $596M | $603M | $669M | $689M | $726M | $1.1B | $1.1B |
| Shareholders' equity | $151M | $185M | $216M | $188M | $239M | $262M | $283M | $257M | $286M | $385M |
| Net debt | $192M | $201M | $160M | $182M | $247M | $214M | $293M | $241M | $564M | -$61M |
Cash flow
Fiscal years, from Phibro Animal Health's 10-K filings with the SEC.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $98M | $70M | $47M | $59M | $48M | $32M | $13M | $88M | $80M | $69M |
| Capital spending | $21M | $19M | $30M | $34M | $29M | $37M | $52M | $41M | $38M | $59M |
| Free cash flow | $78M | $51M | $17M | $25M | $19M | -$5M | -$38M | $46M | $42M | $10M |
| Stock-based compensation | $0 | $334,000 | $2M | $2M | $1M | — | — | $475,000 | $717,000 | $2M |
| Dividends paid | $16M | $16M | $19M | $19M | $19M | $19M | $19M | $19M | $19M | $19M |
| Net borrowing | $250M | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | 10.1% | 6.3% | 2.1% | 3.2% | 2.3% | -0.6% | -3.9% | 4.6% | 3.2% | 0.6% |
| Dividends per share | $0.40 | $0.40 | $0.46 | $0.48 | $0.48 | $0.48 | $0.48 | $0.48 | $0.48 | $0.48 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PAHC.
Open PAHC in InvestinglyQuestions
What was Phibro Animal Health's revenue in 2026?
$1.5B in fiscal 2026, from its 10-K filing.
How much free cash flow does Phibro Animal Health generate?
$10M in fiscal 2026 (operating cash flow minus capital spending).
From Phibro Animal Health's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.